105 related articles for article (PubMed ID: 1542948)
1. Immunogenicity of measles vaccine from a hospital based and outreach programme in rural Kenya.
Kaan JA; van Vlokhoven PC; Schneeberger PM; Nijhof W
Trop Doct; 1992 Jan; 22(1):30-2. PubMed ID: 1542948
[TBL] [Abstract][Full Text] [Related]
2. Study of antibody titres after measles vaccination: fever within 7 days of vaccination and efficacy of booster doses.
Egami T; Egami K; Tanoue A
Arch Dis Child; 2008 Apr; 93(4):319-20. PubMed ID: 17488762
[TBL] [Abstract][Full Text] [Related]
3. Rural Kenya: measles during pregnancy and early infancy.
Arya SC; Agarwal N
J Infect Dis; 2006 Jan; 193(1):165-6; author reply 166-7. PubMed ID: 16323147
[No Abstract] [Full Text] [Related]
4. Haemagglutination inhibition antibody levels one year after natural measles infection and vaccination.
Eghafona NO; Ahmad AA; Ezeokoli CD; Emejuaiwe SO
Microbios; 1991; 67(274):33-6. PubMed ID: 1758308
[TBL] [Abstract][Full Text] [Related]
5. Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: results from five randomised controlled trials.
Crawley J; Sismanidis C; Goodman T; Milligan P;
Lancet; 2012 Sep; 380(9846):1001-10. PubMed ID: 22850358
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of measles antibodies before and after vaccination in previously unvaccinated children of the Cordillera Province (Santa Cruz Department, Bolivia).
Guglielmetti P; Bianchi Bandinelli ML; Bartoloni A; Gamboa H; Roselli M; Valensin PE
J Trop Med Hyg; 1994 Aug; 97(4):231-5. PubMed ID: 8064946
[TBL] [Abstract][Full Text] [Related]
7. Measles antibodies and response to vaccination in children aged less than 14 months: implications for age of vaccination.
Borràs E; Urbiztondo L; Costa J; Batalla J; Torner N; Plasencia A; Salleras L; Domínguez À;
Epidemiol Infect; 2012 Sep; 140(9):1599-606. PubMed ID: 22074684
[TBL] [Abstract][Full Text] [Related]
8. [A new combined vaccine against yellow fever and measles in infants aged 6 to 24 months in Mali].
Soula G; Sylla A; Pichard E; Kodio B; Bentejac MC; Teulières L; Saliou P
Bull Soc Pathol Exot; 1991; 84(5 Pt 5):885-97. PubMed ID: 1819436
[TBL] [Abstract][Full Text] [Related]
9. Head-to-head immunogenicity comparison of Edmonston-Zagreb vs. AIK-C measles vaccine strains in infants aged 8-12 months: A randomized clinical trial.
Izadi S; Zahraei SM; Salehi M; Mohammadi M; Tabatabaei SM; Mokhtari-Azad T
Vaccine; 2018 Jan; 36(5):631-636. PubMed ID: 29289382
[TBL] [Abstract][Full Text] [Related]
10. Seroconversion after measles vaccination at nine and fifteen months of age.
Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
[TBL] [Abstract][Full Text] [Related]
11. Measles immunity in the first year after birth and the optimum age for vaccination in Kenyan children. Collaborative study by the Ministry of Health of Kenya and the World Health Organization.
Bull World Health Organ; 1977; 55(1):21-31. PubMed ID: 302153
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of standard dose Edmonston-Zagreb measles vaccine in highland Papua New Guinean children from four months of age.
Rogers S; Sanders RC; Alpers MP
J Trop Med Hyg; 1991 Apr; 94(2):88-91. PubMed ID: 2023293
[TBL] [Abstract][Full Text] [Related]
13. Immune status following measles vaccination in infants and evaluation for the need of revaccination.
Dutta AK; Singhal PK; Khare S; Kumari S; Mathur R; Mullick DN
Indian Pediatr; 1989 Aug; 26(8):765-72. PubMed ID: 2620977
[TBL] [Abstract][Full Text] [Related]
14. Measles vaccine potency and sero-conversion rates among infants receiving measles immunization in Ilorin, Kwara State, Nigeria.
Fowotade A; Okonko IO; Nwabuisi C; Bakare RA; Fadeyi A; Adu FD
J Immunoassay Immunochem; 2015; 36(2):195-209. PubMed ID: 24825255
[TBL] [Abstract][Full Text] [Related]
15. Low seroconversion rates to measles vaccine among children in Nigeria.
Adu FD; Akinwolere OA; Tomori O; Uche LN
Bull World Health Organ; 1992; 70(4):457-60. PubMed ID: 1394778
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of standard-titer AIK-C measles vaccine in nine-month-old infants.
Tsai HY; Huang LM; Shih YT; Chen JM; Jiang TM; Tsai CH; Lee CY
Viral Immunol; 1999; 12(4):343-8. PubMed ID: 10630793
[TBL] [Abstract][Full Text] [Related]
17. Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa.
Benn CS; Aaby P; Balé C; Olsen J; Michaelsen KF; George E; Whittle H
Lancet; 1997 Jul; 350(9071):101-5. PubMed ID: 9228962
[TBL] [Abstract][Full Text] [Related]
18. Measles in Tanzania: antibody response in children after vaccination and antibody state of mothers and newborns.
de Haas PW; Masurel N; Anker WJ
Trans R Soc Trop Med Hyg; 1983; 77(2):267-70. PubMed ID: 6868109
[TBL] [Abstract][Full Text] [Related]
19. Optimal age for vaccinating Nigerian children against measles. II. Seroconversion to measles vaccine in different age groups.
Ogunmekan DA; Harry TO
Trop Geogr Med; 1981 Dec; 33(4):379-82. PubMed ID: 7342385
[TBL] [Abstract][Full Text] [Related]
20. Measles antibody levels in children of rural and urban areas of Nigeria following vaccination campaign.
Eghafona NO; Odama LE; Emejuaiwe SO; Obineche EN; Tafida DS
Epidemiol Infect; 1987 Aug; 99(1):85-9. PubMed ID: 3609176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
